Wall Street brokerages expect Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) to announce earnings per share of $1.55 for the current quarter, according to Zacks. Seven analysts have made estimates for Gilead Sciences’ earnings. The highest EPS estimate is $1.73 and the lowest is $1.29. Gilead Sciences reported earnings per share of $1.87 during the same quarter last year, which would suggest a negative year over year growth rate of 17.1%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Gilead Sciences will report full-year earnings of $6.55 per share for the current financial year, with EPS estimates ranging from $6.42 to $6.94. For the next year, analysts expect that the business will report earnings of $6.34 per share, with EPS estimates ranging from $4.97 to $7.30. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Gilead Sciences.
Gilead Sciences (NASDAQ:GILD – Get Rating) last announced its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.32. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.28 billion. Gilead Sciences had a return on equity of 44.98% and a net margin of 16.43%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.08 earnings per share.
Shares of NASDAQ GILD opened at $60.31 on Tuesday. The business’s 50 day moving average price is $60.51 and its two-hundred day moving average price is $65.60. The company has a market cap of $75.62 billion, a PE ratio of 16.85, a price-to-earnings-growth ratio of 0.42 and a beta of 0.38. The company has a quick ratio of 1.23, a current ratio of 1.54 and a debt-to-equity ratio of 1.74. Gilead Sciences has a twelve month low of $57.19 and a twelve month high of $74.12.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 29th. Investors of record on Wednesday, June 15th will be paid a $0.73 dividend. This represents a $2.92 annualized dividend and a dividend yield of 4.84%. The ex-dividend date of this dividend is Tuesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 81.56%.
In related news, EVP Brett A. Pletcher sold 1,691 shares of the business’s stock in a transaction that occurred on Wednesday, February 9th. The stock was sold at an average price of $63.89, for a total value of $108,037.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 3,634 shares of the company’s stock in a transaction on Friday, March 11th. The stock was sold at an average price of $58.24, for a total value of $211,644.16. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Landmark Wealth Management LLC bought a new stake in Gilead Sciences during the first quarter worth $30,000. FSB Premier Wealth Management Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter worth $28,000. Joseph P. Lucia & Associates LLC acquired a new position in shares of Gilead Sciences during the first quarter worth $25,000. OLD Second National Bank of Aurora increased its holdings in shares of Gilead Sciences by 46.3% during the third quarter. OLD Second National Bank of Aurora now owns 439 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 139 shares in the last quarter. Finally, Capital Advisors Ltd. LLC increased its holdings in shares of Gilead Sciences by 127.6% during the fourth quarter. Capital Advisors Ltd. LLC now owns 446 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 250 shares in the last quarter. Hedge funds and other institutional investors own 80.16% of the company’s stock.
About Gilead Sciences (Get Rating)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
- GitLab Stock is Trying to Put in a Bottom Here
- It’s Time to Book an Appointment for Teladoc Stock
- Saia Growth Accelerates But It May Not Matter
- onsemi Is A Deep-Value In The Chip Sector
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.